Inhibikase Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €280.70M +203.0% €137.62M +9,701.8% 49.0% +0.48 pp N/A N/A
    (estimated) €92.64M +∞% €1.40M -102.7% 1.5% +0.015 pp N/A N/A
    (estimated) N/A -€52.89M +31.3% N/A N/A N/A
    (estimated) €0.00 +NaN% -€40.28M +31.8% N/A N/A N/A
    (estimated) €0.00 +NaN% -€30.55M +29.7% N/A N/A N/A
    €0.00 -100.0% -€23.56M +44.6% N/A -€16.39M +6.0% N/A
    €223.01K +111.0% -€16.29M +6.3% -7,304.8% +72 pp -€15.47M +5.6% -6,937.0% +69 pp
    €105.68K -96.0% -€15.33M +20.9% -14,505.2% -140 pp -€14.65M +19.7% -13,859.2% -130 pp
    €2.65M +343.9% -€12.68M +414.6% -477.5% -0.66 pp -€12.24M +1,165.9% -461.1% -3.0 pp
    €597.95K -37.8% -€2.46M -49.9% -411.9% +1.0 pp -€966.83K +233.8% -161.7% -1.3 pp
    €961.17K -72.2% -€4.92M +167.0% -511.9% -4.6 pp -€289.61K -147.3% -30.1% -0.48 pp
    €3.46M +96.1% -€1.84M +393.6% -53.3% -0.32 pp €612.09K -665.7% 17.7% +0.24 pp
    €1.76M +113.0% -€373.32K -30.6% -21.2% +0.44 pp -€108.20K +327.4% -6.1% -0.031 pp
    €828.17K -€538.26K -65.0% -€25.32K -3.1%

    Notifications